ArticleACS omega2020
Doxorubicin Loading on Functional Graphene as a Promising Nanocarrier Using Ternary Deep Eutectic Solvent Systems.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 72 citations in OpenAlex.
- FeRSC advances · 2026Article
- Crumpled Graphene Oxide Loaded with Anticancer Agents Synthesized by a Single-Step Aerosol Method for Drug Delivery.ACS omega · 2026Article
- Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery.Cancers · 2025Review
- Utilizing nanomaterials for cancer treatment and diagnosis: an overview.Discover nano · 2024Review
- Preparation and Evaluation of pH-Sensitive Chitosan/Alginate Nanohybrid Mucoadhesive Hydrogel Beads: An Effective Approach to a Gastro-Retentive Drug Delivery System.Pharmaceutics · 2024Article
- Magnetic graphene oxide nanosheets with amidoamine dendronized crosslinks for dual pH and redox-sensitive doxorubicin delivery.BMC chemistry · 2024Article
- Radiolabeled florescent-magnetic graphene oxide nanosheets: probing the biodistribution of a potential PET-MRI hybrid imaging agent for detection of fibrosarcoma tumor.Annals of nuclear medicine · 2024Article
- From Nature to Innovation: The Uncharted Potential of Natural Deep Eutectic Solvents.Molecules (Basel, Switzerland) · 2023Review
- Evaluation of drug carrier hepatotoxicity using primary cell culture models.Nanomedicine : nanotechnology, biology, and medicine · 2023Article
- Ginsenoside Rg3 Reduces the Toxicity of Graphene Oxide Used for pH-Responsive Delivery of Doxorubicin to Liver and Breast Cancer Cells.Pharmaceutics · 2023Article
- Influence of GO-Antisense miRNA-21 on the Expression of Selected Cytokines at Glioblastoma Cell Lines.International journal of nanomedicine · 2023Article
- Green decoration of graphene oxide Nano sheets with gelatin and gum Arabic for targeted delivery of doxorubicin.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- Cancer-Related Intracellular Signalling Pathways Activated by DOXorubicin/Cyclodextrin-Graphene-Based Nanomaterials.Biomolecules · 2022Article
- Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies.Journal of nanobiotechnology · 2021Review
- Recent advances in carbon nanomaterials for biomedical applications: A review.Current opinion in biomedical engineering · 2021Review
- Deep Eutectic Solvents as Active Pharmaceutical Ingredient Delivery Systems in the Treatment of Metabolic Related Diseases.Frontiers in pharmacology · 2021Review
- Synthesis and Cytotoxic Evaluation ofACS omega · 2020Article
- Hydrophobic Modification of Cellulose Nanocrystals from Bamboo Shoots Using Rarasaponins.ACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of graphene in the field of drug delivery has attracted massive interest among researchers. However, the high toxicity of graphene has been a drawback for its use in drug delivery. Therefore, to enhance the biocompatibility of graphene, a new route was developed using ternary natural deep eutectic solvents (DESs) as functionalizing agents, which have the capability to incorporate various functional groups and surface modifications. Physicochemical characterization analyses, including field emission scanning electron microscope, fourier-transform infrared spectroscopy, Raman spectroscopy, Brunauer-Emmett-Teller, X-ray diffraction, and energy dispersive X-ray, were used to verify the surface modifications introduced by the functionalization process. Doxorubicin was loaded onto the DES-functionalized graphene. The results exhibited significantly improved drug entrapment efficiency (EE) and drug loading capacity (DLC) compared with pristine graphene and oxidized graphene. Compared with unfunctionalized graphene, functionalization with DES choline chloride (ChCl):sucrose:water (4:1:4) resulted in the highest drug loading capacity (EE of 51.84% and DLC of 25.92%) followed by DES ChCl:glycerol:water (1:2:1) (EE of 51.04% and DLC of 25.52%). Following doxorubicin loading, graphene damaged human breast cancer cell line (MCF-7) through the generation of intracellular reactive oxygen species (>95%) and cell cycle disruption by increase in the cell population at S phase and G2/M phase. Thus, DESs represent promising green functionalizing agents for nanodrug carriers. To the best of our knowledge, this is the first time that DES-functionalized graphene has been used as a nanocarrier for doxorubicin, illustrating the potential application of DESs as functionalizing agents in drug delivery systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.